<p>这家生物科技公司在香港股市强势首秀，推出了一种针对性 “合成致死” 药物，可以消灭突变的癌细胞。</p>
<p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/05/14035138/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_14-5-2026_115044_thebambooworks.com_-1024x682.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/05/14035138/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_14-5-2026_115044_thebambooworks.com_-1024x682.jpeg"/></p>
<p><em>图片来源：Bamboo Works</em></p>
<h4><strong>关键要点：</strong></h4>
<ul>
<li>该公司的 PARP 抑制剂药物用于晚期癌症，去年在中国获得批准，并被纳入公共医疗保险计划。\n- 尽管研发预算庞大，Impact Therapeutics 仍然深陷亏损，需要通过首次公开募股（IPO）筹集资金以投入药物研发。</li>
</ul>
<p>随着抗癌斗争进入精准医疗时代，投资者开始押注一种新型药物，这种药物可以利用肿瘤细胞的遗传弱点。</p>
<p>这些 “合成致死” 疗法旨在作用于已经失去两条蛋白质通路之一的突变细胞。通过抑制第二条通路，这些药物可以消灭癌细胞，而不损害健康组织。</p>
<p>香港股市在 5 月 13 日迎来了首个专门制造这些抗癌药物的公司——<strong>Impact Therapeutics Inc.</strong>（7630.HK），其首日交易表现惊艳。首日股价翻倍，收于 41.86 港元，首次公开募股（IPO）超额认购超过 2000 倍。</p>
<p>Impact Therapeutics 以 20.1 港元的价格出售了约 4198 万股，定价位于指引范围的高端，筹集了约 8.44 亿港元（1.08 亿美元）的总收入，净收益约为 7.59 亿港元，此次 IPO 由高盛和中金公司共同赞助。</p>
<p>该公司成立于 2009 年，专注于合成致死技术，针对已经失去两条修复 DNA 途径之一的癌细胞。当药物阻断备用通路时，肿瘤细胞会积累损伤，最终在一种称为 PARP 抑制的过程中死亡。作为 PARP 抑制剂设计的药物现在广泛用于治疗与 BRCA 基因突变相关的卵巢癌、乳腺癌和其他癌症。</p>
<p>根据招股说明书，该公司的核心产品是 senaparib，一种自研的 PARP1/2 抑制剂，于 2025 年 1 月在中国获得批准。该药物可以阻止酶修复细胞 DNA，是公司首个商业产品，旨在用于经过化疗的晚期卵巢癌患者。临床数据显示，senaparib 降低了疾病进展或死亡的风险 57%，并可能为无论是否有 BRCA 突变的癌症患者带来更广泛的益处。</p>
<p>该药物于去年 12 月被纳入中国可报销药物名单，为其更广泛的应用铺平了道路。通过与华东医药的合作，senaparib 已经覆盖了中国超过 900 家医疗机构。除了 senaparib，该公司的研发管线还包括 11 种候选药物，包括下一代 PARP1 选择性抑制剂和 ATR 抑制剂，这些药物也阻断 DNA 修复，目前正在临床开发中。</p>
<h4><strong>明星股东</strong></h4>
<p>作为一家刚刚开始将药物推向市场的生物科技公司，Impact Therapeutics 仍然深陷亏损。根据招股说明书，该公司在 2024 年的收入为 3355 万元，主要来自一项重大授权交易，2025 年收入为 3825 万元，其中包括 senaparib 上市后的 2020 万元销售额。</p>
<p>该公司在同一时期的年度亏损分别为 2.55 亿元和 2.96 亿元，主要由于两年内研发支出达到 3.79 亿元。到 2025 年底，现金及现金等价物为 2.59 亿元，足以支持当前烧钱率下约一年的活动，使得 IPO 变得愈发紧迫。约 51% 的 IPO 收益将用于进一步开发和商业化 senaparib，31% 将投资于其他关键管线产品。随着资金投入药物开发，盈利仍然遥遥无期。</p>
<p>根据招股说明书引用的一份报告，合成致死市场具有显著的增长潜力。研究预测，精准药物的全球市场将从 2024 年的 43 亿美元扩展到 2029 年的 87 亿美元，但该领域的竞争非常激烈。在 PARP 抑制剂领域，阿斯利康的奥拉帕利和恒瑞医药的氟唑帕利已经享有先发优势。虽然 senaparib 在患者覆盖面上有所区别，但在日益拥挤的市场中仍面临激烈挑战。</p>
<p>在上市之前，Impact Therapeutics 完成了多轮融资，得到了包括 Lilly Asia Ventures、腾讯、君实生物和药明康德等高知名度投资者的支持。此次 IPO 还吸引了六位基石投资者，合计认购金额约 3587 万美元。在腾讯和 Lilly Asia Ventures 等现有股东的支持下，此次举措还吸引了公共资金和国有资本投资者，包括瑞源基金和江北新区国有资本。</p>
<p>根据 IPO 定价，Impact Therapeutics 的市值约为 60.1 亿港元。以 2025 年的收入为基准，该公司的市销率约为 145 倍——即使在香港上市的生物科技公司中也算高。随着 senaparib 在中国的报销计划下销售量的增加，该公司的 95.9% 的高毛利率可能会受到国家驱动的降价压力。</p>
<p>在这种背景下，投资者将密切关注 Impact Therapeutics 是否能够实现突破性的收入增长，以证明其高估值的合理性。</p>
<p><em>要订阅 Bamboo Works 每周的免费通讯，请点击</em> 这里</p>
<p><strong><em>Benzinga 免责声明：本文来自一位未付费的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>

英派药业-B

<p>影响治疗公司是一家专注于合成致死药物的生物技术公司，在香港股市表现强劲，首日股价翻倍。该公司通过首次公开募股（IPO）筹集了约 8.44 亿港元（1.08 亿美元），认购超额超过 2000 倍。其核心产品 senaparib 是一种在中国获批用于晚期卵巢癌的 PARP 抑制剂。尽管研发损失显著，该公司计划利用 IPO 所得进一步开发 senaparib 及其他在研药物，瞄准日益增长的精准癌症治疗市场</p>

<p><em>The biotech scored a strong debut on the Hong Kong stock market after launching a targeted &#34;synthetic lethality&#34; drug that can kill off mutated cancer cells</em></p>
<div class="lb-trans"><p>这家生物科技公司在香港股市强势首秀，推出了一种针对性 “合成致死” 药物，可以消灭突变的癌细胞。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2026/05/14035138/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_14-5-2026_115044_thebambooworks.com_-1024x682.jpeg" alt="" original-src="https://contributor-assets.benzinga.com/wp-content/uploads/2026/05/14035138/%E5%B1%8F%E5%B9%95%E6%88%AA%E5%9B%BE_14-5-2026_115044_thebambooworks.com_-1024x682.jpeg"/></p>
<p><em>image credit: Bamboo Works</em></p>
<div class="lb-trans"><p><em>图片来源：Bamboo Works</em></p>
</div><h4><strong>Key Takeaways:</strong></h4>
<div class="lb-trans"><h4><strong>关键要点：</strong></h4>
</div><ul>
<li>The company's PARP inhibitor drug for advanced cancers was approved in China last year and is being covered by the public health insurance program</li>
<li>With a big R&amp;D budget, Impact Therapeutics remains deeply in the red and needed IPO cash to pump into its drug pipeline</li>
</ul>
<div class="lb-trans"><ul>
<li>该公司的 PARP 抑制剂药物用于晚期癌症，去年在中国获得批准，并被纳入公共医疗保险计划。\n- 尽管研发预算庞大，Impact Therapeutics 仍然深陷亏损，需要通过首次公开募股（IPO）筹集资金以投入药物研发。</li>
</ul>
</div><p>As the battle against cancer enters an era of precision medicine, investors are starting to bet on a new type of drug that can exploit genetic weaknesses in tumor cells.</p>
<div class="lb-trans"><p>随着抗癌斗争进入精准医疗时代，投资者开始押注一种新型药物，这种药物可以利用肿瘤细胞的遗传弱点。</p>
</div><p>These &#34;synthetic lethality&#34; therapies are designed to work on mutated cells that have already lost one of the two protein pathways they use to keep growing. By inhibiting the second route, the drugs can wipe out cancer cells, leaving healthy tissue unharmed.</p>
<div class="lb-trans"><p>这些 “合成致死” 疗法旨在作用于已经失去两条蛋白质通路之一的突变细胞。通过抑制第二条通路，这些药物可以消灭癌细胞，而不损害健康组织。</p>
</div><p>The Hong Kong stock market welcomed its first maker of these specialized anti-cancer drugs on May 13, when <strong>Impact Therapeutics Inc.</strong> (7630.HK) pulled off a stunning debut. Its shares doubled on the first day of trade, closing at HK$41.86, after a <strong>public offeri ng</strong> that was oversubscribed by more than 2000 times.</p>
<div class="lb-trans"><p>香港股市在 5 月 13 日迎来了首个专门制造这些抗癌药物的公司——<strong>Impact Therapeutics Inc.</strong>（7630.HK），其首日交易表现惊艳。首日股价翻倍，收于 41.86 港元，首次公开募股（IPO）超额认购超过 2000 倍。</p>
</div><p>Impact Therapeutics sold about 41.98 million shares at HK$20.1, pricing the offer at the top end of the indicative range, to deliver gross proceeds of about HK$844 million ($108 million) and net returns of about HK$759 million in an IPO jointly sponsored by Goldman Sachs and CICC.</p>
<div class="lb-trans"><p>Impact Therapeutics 以 20.1 港元的价格出售了约 4198 万股，定价位于指引范围的高端，筹集了约 8.44 亿港元（1.08 亿美元）的总收入，净收益约为 7.59 亿港元，此次 IPO 由高盛和中金公司共同赞助。</p>
</div><p>Founded in 2009, the innovative drug company specializes in synthetic lethality techniques, targeting cancer cells that have already lost one of two ways to repair their DNA. When the drug blocks the back-up path, the tumor cell accumulates damage and eventually dies in a process known as PARP inhibition. Drugs designed as PARP inhibitors are now widely used to treat ovarian, breast and other cancers associated with mutations of the BRCA gene.</p>
<div class="lb-trans"><p>该公司成立于 2009 年，专注于合成致死技术，针对已经失去两条修复 DNA 途径之一的癌细胞。当药物阻断备用通路时，肿瘤细胞会积累损伤，最终在一种称为 PARP 抑制的过程中死亡。作为 PARP 抑制剂设计的药物现在广泛用于治疗与 BRCA 基因突变相关的卵巢癌、乳腺癌和其他癌症。</p>
</div><p>The company's core product is senaparib, a self-developed PARP1/2 inhibitor approved for use in China in January 2025, according to the prospectus. The drug, which prevents enzymes from repairing cellular DNA, is the company's first commercial product, aimed at patients with advanced ovarian cancer after a round of chemotherapy. Clinical data indicated senaparib reduced the risk of disease progression or death by 57% and could deliver benefits more widely for cancer patients whether they have the BRCA mutation or not.</p>
<div class="lb-trans"><p>根据招股说明书，该公司的核心产品是 senaparib，一种自研的 PARP1/2 抑制剂，于 2025 年 1 月在中国获得批准。该药物可以阻止酶修复细胞 DNA，是公司首个商业产品，旨在用于经过化疗的晚期卵巢癌患者。临床数据显示，senaparib 降低了疾病进展或死亡的风险 57%，并可能为无论是否有 BRCA 突变的癌症患者带来更广泛的益处。</p>
</div><p>The drug was added to China's list of reimbursable drugs last December, opening the way for its wider adoption. Through a partnership with Huadong Medicine, senaparib has already reached more than 900 medical institutions across China. Beyond senaparib, the company's pipeline includes 11 candidate drugs, including next-generation PARP1 selective inhibitors and ATR inhibitors, which also block DNA repair, that are in clinical development.</p>
<div class="lb-trans"><p>该药物于去年 12 月被纳入中国可报销药物名单，为其更广泛的应用铺平了道路。通过与华东医药的合作，senaparib 已经覆盖了中国超过 900 家医疗机构。除了 senaparib，该公司的研发管线还包括 11 种候选药物，包括下一代 PARP1 选择性抑制剂和 ATR 抑制剂，这些药物也阻断 DNA 修复，目前正在临床开发中。</p>
</div><h4><strong>Star-studded stakeholders</strong></h4>
<div class="lb-trans"><h4><strong>明星股东</strong></h4>
</div><p>As a biotech company that is only just starting to bring its drugs to market, Impact Therapeutics remains deeply in the red. According to the prospectus, the company generated revenue of 33.55 million yuan in 2024, mainly from a major out-licensing deal, and 38.25 million yuan in 2025, including 20.2 million yuan in sales after the senaparib launch.</p>
<div class="lb-trans"><p>作为一家刚刚开始将药物推向市场的生物科技公司，Impact Therapeutics 仍然深陷亏损。根据招股说明书，该公司在 2024 年的收入为 3355 万元，主要来自一项重大授权交易，2025 年收入为 3825 万元，其中包括 senaparib 上市后的 2020 万元销售额。</p>
</div><p>The company posted annual losses of 255 million yuan and 296 million yuan over the same period, largely due to R&amp;D spending amounting to 379 million yuan over the two years. Cash and cash equivalents stood at 259 million yuan by the end of 2025, enough to fund about a year of activities at the current burn rate and making an IPO increasingly urgent. About 51% of the IPO proceeds will go towards further developing and commercializing senaparib, while 31% are set to be invested in other key pipeline products. As capital is pumped into drug development, profitability remains a long way off.</p>
<div class="lb-trans"><p>该公司在同一时期的年度亏损分别为 2.55 亿元和 2.96 亿元，主要由于两年内研发支出达到 3.79 亿元。到 2025 年底，现金及现金等价物为 2.59 亿元，足以支持当前烧钱率下约一年的活动，使得 IPO 变得愈发紧迫。约 51% 的 IPO 收益将用于进一步开发和商业化 senaparib，31% 将投资于其他关键管线产品。随着资金投入药物开发，盈利仍然遥遥无期。</p>
</div><p>The synthetic lethality market offers significant growth potential, according to a report cited in the prospectus. The study predicted the global market for the precision drugs would expand from $4.3 billion in 2024 to $8.7 billion by 2029, but competition within the arena is fierce. In the PARP inhibitor space, AstraZeneca's olaparib and Hengrui Pharma's fluzoparib already enjoy first-mover advantages. While senaparib differentiates itself with broader patient coverage, it still faces a stiff challenge to catch up in an increasingly crowded market.</p>
<div class="lb-trans"><p>根据招股说明书引用的一份报告，合成致死市场具有显著的增长潜力。研究预测，精准药物的全球市场将从 2024 年的 43 亿美元扩展到 2029 年的 87 亿美元，但该领域的竞争非常激烈。在 PARP 抑制剂领域，阿斯利康的奥拉帕利和恒瑞医药的氟唑帕利已经享有先发优势。虽然 senaparib 在患者覆盖面上有所区别，但在日益拥挤的市场中仍面临激烈挑战。</p>
</div><p>Before going public, Impact Therapeutics completed multiple funding rounds backed by high-profile investors including Lilly Asia Ventures, Tencent, Junshi Biosciences and WuXi AppTec. The IPO also attracted six cornerstone investors with combined subscriptions of about $35.87 million. On top of support from existing shareholders such as Tencent and Lilly Asia Ventures, the move attracted public funds and state-backed investors including Ruiyuan Fund and Jiangbei New Area state-owned capital.</p>
<div class="lb-trans"><p>在上市之前，Impact Therapeutics 完成了多轮融资，得到了包括 Lilly Asia Ventures、腾讯、君实生物和药明康德等高知名度投资者的支持。此次 IPO 还吸引了六位基石投资者，合计认购金额约 3587 万美元。在腾讯和 Lilly Asia Ventures 等现有股东的支持下，此次举措还吸引了公共资金和国有资本投资者，包括瑞源基金和江北新区国有资本。</p>
</div><p>Based on the IPO pricing, Impact Therapeutics commands a market value of about HK$6.01 billion. Using 2025 revenue as a benchmark, the company is trading at a price-to-sales ratio of roughly 145 times — high even among Hong Kong's listed biotechs. As senaparib sales ramp up this year through China's reimbursement program, the company's exceptionally high 95.9% gross margin will likely come under pressure from state-driven price cuts.</p>
<div class="lb-trans"><p>根据 IPO 定价，Impact Therapeutics 的市值约为 60.1 亿港元。以 2025 年的收入为基准，该公司的市销率约为 145 倍——即使在香港上市的生物科技公司中也算高。随着 senaparib 在中国的报销计划下销售量的增加，该公司的 95.9% 的高毛利率可能会受到国家驱动的降价压力。</p>
</div><p>Against that backdrop, investors will be watching to see if Impact Therapeutics can deliver breakout revenue growth to justify its elevated valuation.</p>
<div class="lb-trans"><p>在这种背景下，投资者将密切关注 Impact Therapeutics 是否能够实现突破性的收入增长，以证明其高估值的合理性。</p>
</div><p><em>To subscribe to Bamboo Works weekly free newsletter, click</em> here</p>
<div class="lb-trans"><p><em>要订阅 Bamboo Works 每周的免费通讯，请点击</em> 这里</p>
</div><p><strong><em>Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.</em></strong></p>
<div class="lb-trans"><p><strong><em>Benzinga 免责声明：本文来自一位未付费的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>
</div>

精准药物制造商英派药业-B 点燃了 IPO 狂潮